Insulin Sensitizers Market

Insulin sensitizers are medications that improve insulin sensitivity and reduce blood sugar levels. These are also known as blood sugar normalizing agents and euglycemics, and these help in returning blood glucose to the normal range without using insulin. These work by increasing liver, muscle and fat cells' sensitivity to insulin. There are several different types of insulin sensitizers including metformin (Met), pioglitazone (Pio), thiazolidinediones (TZDs), and inositols.

Market Dynamics

Global insulin sensitizers market growth is driven by increased prevalence of diabetes, especially type 2 diabetes. Insulin sensitizers are frequently used to increase insulin sensitivity and manage blood glucose levels in the treatment of type 2 diabetes. Type 2 diabetes and insulin resistance are both significantly increased by obesity. Effective insulin sensitizer helps in controlling insulin resistance and related metabolic diseases due to rising prevalence of obesity worldwide. The ongoing research and development activities have introduced new and enhanced insulin sensitizers that creates innovative compounds and formulation methods, and improves the efficacy and safety profiles of drugs that treat insulin sensitivity. Furthermore, the governments have taken several initiatives to combat diabetes. The plans and the programs focus on spreading knowledge about diabetes, early detection of diabetes and facilitating necessary and affordable treatments like insulin sensitizers.

Like any drugs, insulin sensitizers have potential side effects like weight gain, fluid retention, bone fractures, and an elevated risk of heart failure. Specific kinds of insulin sensitizers such as thiazolidinediones (TZDs) may create worries about its safety concern, thus, restricting their use and make them difficult to embrace widely.

Key features of the study:

• This report provides in-depth analysis of the global insulin sensitizers market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global insulin sensitizers market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Eli Lilly and Company, Novo Nordisk, Sanofi, Merck & Co., Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Takeda Pharmaceutical
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global insulin sensitizers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global insulin sensitizers market

Insulin Sensitizers Market Detailed Segmentation:

• By Type:
  • Thiazolidinediones (TZDs)
  • Biguanides
  • Incretin-based therapies
  • Others
• By Indication:
  • Type 2 Diabetes
  • Prediabetes
  • Polycystic Ovary Syndrome (PCOS)
• By Route of Administration:
  • Oral
  • Injectable
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East &Africa
• Company Profiles:
  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Merck & Co.
  • Bristol Myers Squibb
  • AstraZeneca
  • Boehringer Ingelheim
  • Johnson & Johnson
  • Takeda Pharmaceutical